HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MARKET ANALYSIS

Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Mar 2025
Code : CMI3790
Pages :201
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Human Immunoglobulin (pH4) for Intravenous Injection Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global human immunoglobulin ph4 for intravenous injection market over the forecast period. This is due to the prevalence of COVID-19 in the region. For instance, according to a report published by WHO on December 2020, there had been 10,336,829 confirmed cases of COVID-19 with 1,127,152 deaths in 2020.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa